Results 41 to 50 of about 182,433 (270)

Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study. [PDF]

Virol J
Zhao J, Bian D, Xie D, Lv J, Lin L, Chen X, Zhang L, Feng B, Xu X, Lu F, Zheng S.   +10 more
europepmc   +2 more sources

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C [PDF]

, 2012
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Jörg Bojunga, Raffaele Malinverni, Gerlach, Tilman J., Gerlach, Tilman J, Tilman J Gerlach, Swiss Hepatitis C Cohort Study Group,, Berg, T., Kutalik, Z., Stephanie Bibert, Christian M Lange, Geier, Andreas, Dufour, Jean-François Jacques, Thomas Berg, Malinverni, Raffaele, Regenass, S., Burgisser, Philippe, Regenass, Stephan, Badenhoop, Klaus, Bojunga, Jörg, Lange, Christian M, Dufour, J. F., Stephan Regenass, Gerlach, Tilman Joern, Swiss Hepatitis C Cohort Study Group, Bochud, P. Y., Dufour, Jean-Francois, Bojunga, J., Andreas Geier, Stefan Zeuzem, Negro, F., Cerny, A., Zoltan Kutalik, Lange, Christian, Pierre-Yves Bochud, Sarrazin, C., Tobias Müller, Sarrazin, Christoph, Lange, C. M., Cerny, Andreas, Kutalik, Zoltán, Bibert, S., Malinverni, R., Moradpour, Darius, Christoph Sarrazin, Burgisser, P., Gerlach, T. J., Moradpour, D., Bibert, Stephanie, Klaus Badenhoop, Zeuzem, S., Negro, Francesco, Müller, Tobias, Badenhoop, K., Andreas Cerny, Bochud, Pierre-Yves, Geier, A., Heim, M. H., Muller, T., Francesco Negro, Berg, Thomas, Markus H Heim, Heim, Markus H., Darius Moradpour, Jean-Francois Dufour, Philippe Burgisser, Heim, Markus H, Zeuzem, Stefan   +66 more
core   +2 more sources

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

Haematologica, 2018
We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative ...
Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, Emmanuel Gyan, Kamel Laribi, Pascale Cony-Makhoul, Jean-Loup Demory, Benoit de Renzis, Christine Dosquet, Jerome Rey, Lydia Roy, Brigitte Dupriez, Laurent Knoops, Laurence Legros, Mohamed Malou, Pascal Hutin, Dana Ranta, Omar Benbrahim, Valérie Ugo, Eric Lippert, Jean-Jacques Kiladjian   +20 more
doaj   +1 more source

ASSESSMENT OF SERUM INTERLEUKIN-10 LEVEL IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN [PDF]

Kafrelsheikh Veterinary Medical Journal, 2014
Hepatitis C virus (HCV) infection is a major health problem. Egypt has the highest prevalence worldwide. Currently, combined pegylated interferon and ribavirin therapy is the standard treatment but the outcome is not satisfactory. The present study aimed
Nilly Helmy Abdalla, A. M. Okasha, S. R., Abdel raheim, Hannan A. Soliman, S. Z. Abd al aziz   +4 more
doaj   +1 more source

Interferon signalling in the liver : implications for the natural course and therapy of hepatitis C [PDF]

, 2012
Hepatitis C virus is a global health concern, estimated to infect 2-3% of the world's population. Inter-individual differences in the course of infection and response to therapy, highlighted by recent genomewide association studies, point to the crucial ...
Makowska, Zuzanna
core   +1 more source

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Haematologica, 2012
The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications.
Krisstina Gowin, Prakash Thapaliya, Jan Samuelson, Claire Harrison, Deepti Radia, Bjorn Andreasson, John Mascarenhas, Alessandro Rambaldi, Tiziano Barbui, Catherine J. Rea, John Camoriano, Amy Gentry, Jean-Jacques Kiladjian, Casey O'Connell, Ruben Mesa   +14 more
doaj   +1 more source

The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin [PDF]

Journal of Microbiology and Infectious Diseases, 2012
The pegylated interferon alpha and ribavirin treatment is well established therapy for hepatitis C virus (HCV) infection.During the treatment alanine aminotransferase (ALT) flare may be observed rarely.A 51-year-old female receiving pegylated interferon ...
Hayati Demiraslan, Zeynep Türe, Ayşegül Ulu Kılıç   +2 more
doaj   +3 more sources

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2012
Introduction. Chronic hepatitis C virus (HCV) infection can progress to liver cirrhosis that causes bleeding from the gastrointestinal tract, liver failure and primary hepatocellular carcinoma.
Delić Dragan, Mitrović Nikola, Popović Nataša, Urošević Aleksandar, Pešić Ivana, Simonović Jasmina, Dulović Olga, Švirtlih Neda   +7 more
doaj   +1 more source

Interferon signaling in viral hepatitis [PDF]

, 2013
Hepatitis C virus (HCV) is a single stranded positive RNA virus classified in 6 different genotypes. Hepatocytes are the main targets of HCV infection. It has been estimated that 60 to 70% of the infected patients develop chronic infection.
Trincucci, Gaia
core   +1 more source

The sustained virologic response of nonresponder hepatitis C virus patients with retreatment

Indian Journal of Pathology and Microbiology, 2011
Background: Pegylated interferon and ribavirin combination therapy remain the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the large number of studies in treatment-naive patients, the effectiveness of retreatment in ...
Sila Cetin Akhan, Erdem Gurel, Murat Sayan   +2 more
doaj   +1 more source